{"id":"NCT00358917","sponsor":"Abbott","briefTitle":"Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects","officialTitle":"A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir (LPV/r) Tablets 800/200 Milligram (mg) Once-Daily (QD) Versus 400/100 mg Twice-Daily (BID) When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-Experienced, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2006-08-01","resultsPosted":"2010-02-01","lastUpdate":"2011-04-11"},"enrollment":599,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Infections"],"interventions":[{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378","lopinavir/ritonavir","Kaletra"]},{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378","lopinavir/ritonavir","Kaletra"]}],"arms":[{"label":"LPV/r 800/200 mg QD Tablet","type":"EXPERIMENTAL"},{"label":"LPV/r 400/100 mg BID Tablet","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to compare the safety, tolerability, and antiviral activity of once-daily (QD) and twice-daily (BID) dosing of the lopinavir/ritonavir (LPV/r) tablet formulation in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in antiretroviral-experienced human immunodeficiency virus type 1 infected subjects with detectable viral load while receiving their current antiretroviral therapy.","primaryOutcome":{"measure":"Percentage of Participants Responding at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm","timeFrame":"Week 48 (End of Study)","effectByArm":[{"arm":"LPV/r 800/200 mg QD Tablet","deltaMin":55.3,"sd":null},{"arm":"LPV/r 400/100 mg BID Tablet","deltaMin":51.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.413"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":300},"commonTop":["Diarrhoea","Nausea","Vomiting","Upper respiratory tract infection","Headache"]}}